About this trial
It has been estimated that 1.7 billion people have tuberculosis (TB) infection; yet current tests are unable to predict which people are at highest risk of developing TB disease, which can be life-threatening. THWART-TB is a prospective longitudinal cohort study of health workers (HWs) in Cape Town, South Africa, where our preliminary data reveals HWs have a high annual TB infection risk (34%). This cohort, who will undergo frequent serial evaluation (every 3 months) with a combination of novel assays never previously evaluated together, presents a unique opportunity to evaluate immune responses at the time of initial infection and to characterize the dynamic profile of these immune responses over time in a high-risk population. The knowledge generated will improve our understanding of TB infection and help to identify which people exposed to TB may remain at risk, enabling us to better target preventive strategies.
Eligibility criteria
Qualifiers
≥18 years old
Health worker
Able to provide informed consent
Disqualifiers
Prior history of TB or known prior positive IGRA
Current or prior history of taking anti-TB treatment
Trial design
Treatments tested in this trial
- TB infection testing
Treatment groups
Sponsors and collaborators
Beth Israel Deaconess Medical Center
Lead sponsor
University of Stellenbosch
Collaborator